Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-28.61M |
| Operating Margin | 0.00% |
| Return on Equity | -49.20% |
| Return on Assets | -19.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.52 |
| Price-to-Book | 0.75 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.63M |
| Float | $5.07M |
| % Insiders | 74.49% |
| % Institutions | 10.97% |
Volatility is currently expanding